PerkinElmer – Consensus indicates 13.6% upside potential

Perkin Elmer with ticker code (PKI) now have 12 analysts covering the stock with the consensus suggesting a buy rating. The target price ranges between 200 and 125 by calculating the average target price we have 171.25. Given that the stock’s previous close was at 150.69, this would indicate that there is 13.6% upside potential. The 50-day MA is at 143.85 and the 200 moving average is now moving to 167.01. The market cap of the company is $19,962 million. Visit the company’s website at: https://www.perkinelmer.com

The potential market capitalization would be $22,686 million based on market consensus.

You can now share it on Stocktwits, just click on the logo below and add the ticker in the text to be seen.

PerkinElmer provides products, services and solutions to the diagnostics, life sciences and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, computational and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life science research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions and services for the environmental, food and industrial markets that enable its customers to understand the health characteristics of various aspects, including the air, water and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricants, petrochemical and polymer industries. The Diagnostics segment provides instruments, reagents, analysis platforms and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. . Its products are used to test and screen for genetic abnormalities, disorders and diseases, including Down syndrome, hypothyroidism, muscular dystrophy, infertility and various metabolic conditions. This segment also develops technologies that enable and support genomics workflows using protein-coupled receptors and next-generation DNA sequencing for applications in oncology, immunodiagnostics and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private health organizations, physicians and government agencies. PerkinElmer was founded in 1937 and is based in Waltham, Massachusetts.

Comments are closed.